Compare CNXN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXN | HRMY |
|---|---|---|
| Founded | 1982 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 1997 | 2020 |
| Metric | CNXN | HRMY |
|---|---|---|
| Price | $89.17 | $37.91 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $48.08 |
| AVG Volume (30 Days) | 136.8K | ★ 965.8K |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | ★ 3.23 | 1.84 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | $8.32 | $18.17 |
| Revenue Next Year | $2.39 | $13.71 |
| P/E Ratio | $26.89 | ★ $20.59 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $54.97 | $25.90 |
| 52 Week High | $96.91 | $43.49 |
| Indicator | CNXN | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 44.03 | 50.13 |
| Support Level | $85.81 | $36.74 |
| Resistance Level | $88.31 | $39.40 |
| Average True Range (ATR) | 2.85 | 1.50 |
| MACD | -0.52 | 0.17 |
| Stochastic Oscillator | 33.39 | 80.36 |
PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.